Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1
Completed
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT02303821
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States
🇺🇸West Virginia University Medicine Childrens, Morgantown, West Virginia, United States
🇹🇷Medical Park Bahcelievler Hastanesi, Istanbul, Turkey
Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)
Completed
- Conditions
- B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 207
- Registration Number
- NCT02303522
- Locations
- 🇮🇹
Research Site, Roma, Italy
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
- Conditions
- Unresected Stage IIIB to IVM1c Melanoma
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Amgen
- Registration Number
- NCT02297529
- Locations
- 🇨🇭
Research Site, Zürich, Switzerland
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 26
- Registration Number
- NCT02291588
A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT02291614
- Locations
- 🇳🇱
Research Site, Groningen, Netherlands
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 170
- Registration Number
- NCT02289417
- Locations
- 🇺🇸
Southern California Research Institute Medical Group, Inc., Los Angeles, California, United States
🇺🇸NYU Langone Long Island Clinical Research Associates, Great Neck, New York, United States
🇺🇸Precision Clinical Research, LLC, Lauderdale Lakes, Florida, United States
A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 75
- Registration Number
- NCT02287610
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 203
- Registration Number
- NCT02279173
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab
Phase 1
Completed
- Conditions
- HyperlipidemiaMixed Dyslipidemia
- Interventions
- Biological: Evolocumab
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 18
- Registration Number
- NCT02275156
- Locations
- 🇺🇸
Research Site, Denver, Colorado, United States
Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 132
- Registration Number
- NCT02274792
- Locations
- 🇨🇦
Research Site, Waterloo, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath